COMPASS Pathways plc
CMPSNasdaqHealthcare · Pharmaceutical Preparations · X0 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$179.0M | −$178.2M | −$136.9M | −$110.4M | −$83.2M | −$51.4M |
| Net income | −$287.9M | −$155.1M | −$118.5M | −$91.5M | −$71.7M | −$60.3M |
| Total assets | $210.3M | $213.7M | $276.0M | $197.3M | $300.9M | $203.5M |
| Total liabilities | $263.2M | $59.0M | $50.2M | $16.0M | $16.5M | $6.9M |
| Equity | −$52.8M | $154.7M | $225.7M | $181.3M | $284.4M | $196.6M |
| EPS (diluted) | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 | $-3.55 |
| Shares out. | 92.7M | 64.2M | 42.8M | 42.0M | 40.0M | 17.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 544.7%
- Return on assets
- −136.8%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 125.1%
- Debt / equity
- —
- Book value / share
- $-0.57
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -20.44distress
- Accruals / assets
- −62.1%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2025-05-28Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
- Phase 2Active Not Recruitingreadout ~2025-09A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
- Phase 3Active Not Recruitingreadout ~2026-02Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
- Phase 2/3Not Yet Recruitingreadout ~2028-11Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Rtw Investments, LpPassive (13G)May 15, 2026
- Ataibeckley Inc.Activist (13D)Feb 17, 2026
- Vivo Opportunity Fund Holdings, L.P.Passive (13G)Nov 14, 2025
- Nantahala Capital Management, LlcPassive (13G)Nov 14, 2025
- Atai Life Sciences N.V.Activist (13D)Oct 29, 2025
- Tcg Crossover Gp I, LlcPassive (13G)Aug 14, 2025
- Integrated Core Strategies (Us) LlcPassive (13G)May 7, 2025
- Goldsmith George JayPassive (13G)Apr 15, 2025
- Citadel Advisors LlcPassive (13G)Feb 14, 2025
- Deep Track Capital, LpPassive (13G)Jan 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 7.7M | 2.0 | -21.2% |
| Apr 30, 2026 | 9.8M | 1.1 | -11.3% |
| Apr 15, 2026 | 11.0M | 7.4 | +23.9% |
| Mar 31, 2026 | 8.9M | 3.9 | +39.5% |
| Mar 13, 2026 | 6.4M | 2.5 | +1.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 28, 2026
- Results of operationsMay 13, 2026
- Results of operationsMar 24, 2026
- Entered a material agreement · Regulation FD disclosureFeb 19, 2026
- Regulation FD disclosure · Other material eventFeb 17, 2026
- Entered a material agreement · New financial obligationJan 7, 2026
- Results of operationsNov 4, 2025
- Director / officer changeOct 29, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.